2-[4-((S)-2-(tert-Butoxyoxalyl-amino)-2-{1-[(S)-2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-phenyl]-malonic acid di-tert-butyl ester | 264131-71-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[4-((S)-2-(tert-Butoxyoxalyl-amino)-2-{1-[(S)-2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-phenyl]-malonic acid di-tert-butyl ester
• 英文别名: ditert-butyl 2-[4-[(2S)-3-[[1-[[(2S)-4-amino-1-(3-naphthalen-1-ylpropylamino)-1,4-dioxobutan-2-yl]carbamoyl]cyclohexyl]amino]-2-[[2-[(2-methylpropan-2-yl)oxy]-2-oxoacetyl]amino]-3-oxopropyl]phenyl]propanedioate
• CAS: 264131-71-7
• 化学式: C₅₀H₆₇N₅O₁₁
• 分子量: 914.109
• InChiKey: RHQPZOXDWLWHGD-BCRBLDSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  66
• 可旋转键数：
  24
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  238
• 氢给体数：
  5
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2-[4-((S)-2-(tert-Butoxyoxalyl-amino)-2-{1-[(S)-2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-phenyl]-malonic acid di-tert-butyl ester 在 三乙基硅烷 、 水 、 三氟乙酸 作用下， 反应 1.0h， 以99%的产率得到2-{4-[(S)-2-{1-[(S)-2-Carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-2-(oxalyl-amino)-ethyl]-phenyl}-malonic acid
  参考文献：
  名称：

  细胞渗透性、不含磷酸盐的 GRB2 SH2 结构域抑制剂的大规模制备

  摘要：

  细胞信号转导抑制剂正在成为包括癌症和糖尿病在内的多种疾病的重要新疗法。异常蛋白酪氨酸激酶依赖性信号传导的拮抗剂特别令人感兴趣 7，其中类似物 14 和 2s 代表了两个值得注意的例子，最近据报道它们在细胞外测定和全细胞制备中均能有效抑制 Grb2 SH2 结构域结合。Grb2 SH2 结构域在多种癌症（包括乳腺癌和白血病）中发挥的核心作用，使 1 和 2 成为有用的药理学工具和治疗剂的潜在价值。以前 1 和 2 都仅以毫克级制备。然而，由于需要显着更大的数量，本文报道了它们通过适用于相关信号转导抑制剂放大的技术在数百毫克规模上的合成。特别值得注意的是应用径向压缩技术以实现近 1 g 规模的最终产品 HPLC 纯化。

  DOI：

  10.1080/00304940009356287
• 作为产物：
  描述：

  N^α-Fmoc-4-(di-tert-butoxycarbonyl-methyl)-L-phenylalanine 在 哌啶 、 N,N′-二叔丁基碳二亚胺 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.17h， 生成 2-[4-((S)-2-(tert-Butoxyoxalyl-amino)-2-{1-[(S)-2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-phenyl]-malonic acid di-tert-butyl ester
  参考文献：
  名称：

  Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2. 4-(2-Malonyl)phenylalanine as a Potent Phosphotyrosyl Mimetic

  摘要：

  Nonhydrolyzable phosphotyrosyl (pTyr) mimetics serve as important components of many competitive Grb2 SH2 domain inhibitors. To date, the most potent of these inhibitors have relied on phosphonate-based structures to replace the 4-phosphoryl group of the parent pTyr residue. Reported herein is the design and evaluation of a new pTyr mimetic, p-malonylphenylalanine (Pmf), which does not contain phosphorus yet, in Grb2 SH2 domain binding systems, approaches the potency of phosphonate-based pTyr mimetics. When incorporated into high affinity Grb2 SH2 domain-directed platforms, Pmf is 15-20 times more potent than the closely related previously reported pTyr mimetic, O-malonyltyrosine (OMT). Pmf-containing inhibitors show inhibition constants as low as 8 nM in extracellular Grb2 binding assays and in whole cell systems, effective blockade of both endogenous Grb2 binding to cognate erbB-2, and downstream MAP kinase activation. Evidence is provided that use of an N-alpha-oxalyl auxiliary enhances effectiveness of Pmf and other inhibitors in both extracellular and intracellular contexts. As one of the most potent Grb2 SH2 domain-directed pTyr mimetics yet disclosed, Pmf may potentially have utility in the design of new chemotherapeutics for the treatment of various proliferative diseases, including breast cancer.

  DOI：

  10.1021/jm9904248

文献信息

• LARGE SCALE PREPARATION OF CELL PERMEABLE, NON-PHOSPHATE-CONTAINING GRB2 SH2 DOMAIN INHIBITORS
  作者：Ding-Guo Liu、Zhu-Jun Yao、Yang Gao、Terrence R. Burke

  DOI：10.1080/00304940009356287

  日期：2000.4

  Inhibitors of cellular signal transduction are emerging as important new therapeutics for several diseases including cancers' and diabetes.' Antagonists of aberrant protein-tyrosine kinasedependent signalling are particularly interesting7 with analogues l4 and 2s representing two noteworthy examples which have been reported recently to potently inhibit Grb2 SH2 domain binding both in extracellular

  细胞信号转导抑制剂正在成为包括癌症和糖尿病在内的多种疾病的重要新疗法。异常蛋白酪氨酸激酶依赖性信号传导的拮抗剂特别令人感兴趣 7，其中类似物 14 和 2s 代表了两个值得注意的例子，最近据报道它们在细胞外测定和全细胞制备中均能有效抑制 Grb2 SH2 结构域结合。Grb2 SH2 结构域在多种癌症（包括乳腺癌和白血病）中发挥的核心作用，使 1 和 2 成为有用的药理学工具和治疗剂的潜在价值。以前 1 和 2 都仅以毫克级制备。然而，由于需要显着更大的数量，本文报道了它们通过适用于相关信号转导抑制剂放大的技术在数百毫克规模上的合成。特别值得注意的是应用径向压缩技术以实现近 1 g 规模的最终产品 HPLC 纯化。
• Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2. 4-(2-Malonyl)phenylalanine as a Potent Phosphotyrosyl Mimetic
  作者：Yang Gao、Juliet Luo、Zhu-Jun Yao、Ribo Guo、Hong Zou、James Kelley、Johannes H. Voigt、Dajun Yang、Terrence R. Burke

  DOI：10.1021/jm9904248

  日期：2000.3.1

  Nonhydrolyzable phosphotyrosyl (pTyr) mimetics serve as important components of many competitive Grb2 SH2 domain inhibitors. To date, the most potent of these inhibitors have relied on phosphonate-based structures to replace the 4-phosphoryl group of the parent pTyr residue. Reported herein is the design and evaluation of a new pTyr mimetic, p-malonylphenylalanine (Pmf), which does not contain phosphorus yet, in Grb2 SH2 domain binding systems, approaches the potency of phosphonate-based pTyr mimetics. When incorporated into high affinity Grb2 SH2 domain-directed platforms, Pmf is 15-20 times more potent than the closely related previously reported pTyr mimetic, O-malonyltyrosine (OMT). Pmf-containing inhibitors show inhibition constants as low as 8 nM in extracellular Grb2 binding assays and in whole cell systems, effective blockade of both endogenous Grb2 binding to cognate erbB-2, and downstream MAP kinase activation. Evidence is provided that use of an N-alpha-oxalyl auxiliary enhances effectiveness of Pmf and other inhibitors in both extracellular and intracellular contexts. As one of the most potent Grb2 SH2 domain-directed pTyr mimetics yet disclosed, Pmf may potentially have utility in the design of new chemotherapeutics for the treatment of various proliferative diseases, including breast cancer.